Expanded Access Program for CT1812 (Zervimesine)

Inclusion Criteria

• •1. Participants must meet either one of the following criteria:
• •1. Randomized participant in protocol COG1201 and completed the study or
• •2. Referred by their treating physician to a participating COG1202 study site with a confirmed diagnosis of probable DLB, provide evidence of a historical MRI (within last 3 months) or CT-Scan (within last 3 months), a baseline Mini Mental Status Examination score (MMSE) of 18 - 27 inclusive and be approved by Sponsor
• •2. Participants must have caregiver(s) / study partner who in the opinion of the site principal investigator, has contact with the study participant for a sufficient number of hours per week to provide informative responses on the protocol assessments, oversee the administration of study drug, and willing and able to participate in study visits and some study assessments. The caregiver/ study partner must also provide informed consent to participate in the study.
• •3. Men or women 50- 86 years of age (inclusive).
• •4. Must have had no clinically relevant findings, other than change for progression of DLB, on historical MRI or CT scan.
• •5. In the opinion of the investigator, must be able to complete all protocol evaluations.